Kamada cosies up with Chiesi for inhaled alpha-1 product
This article was originally published in Scrip
Executive Summary
Kamada of Israel has signed an exclusive distribution agreement with Chiesi Farmaceutici of Italy for Kamada's experimental inhaled alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency (AATD-IH).